- Home
- OPCH vs BPMC Comparison
OPCH vs BPMC Comparison
Compare OPCH & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPCH
- BPMC
- Stock Information
- Founded
- OPCH N/A
- BPMC 2008
- Country
- OPCH United States
- BPMC United States
- Employees
- OPCH N/A
- BPMC N/A
- Industry
- OPCH Medical/Nursing Services
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- OPCH Health Care
- BPMC Health Care
- Exchange
- OPCH Nasdaq
- BPMC Nasdaq
- Market Cap
- OPCH 5.3B
- BPMC 5.8B
- IPO Year
- OPCH N/A
- BPMC 2015
- Fundamental
- Price
- OPCH $31.84
- BPMC $97.17
- Analyst Decision
- OPCH Strong Buy
- BPMC Buy
- Analyst Count
- OPCH 7
- BPMC 21
- Target Price
- OPCH $35.86
- BPMC $124.05
- AVG Volume (30 Days)
- OPCH 2.8M
- BPMC 988.9K
- Earning Date
- OPCH 04-29-2025
- BPMC 05-01-2025
- Dividend Yield
- OPCH N/A
- BPMC N/A
- EPS Growth
- OPCH N/A
- BPMC N/A
- EPS
- OPCH 1.25
- BPMC N/A
- Revenue
- OPCH $5,185,122,000.00
- BPMC $562,121,000.00
- Revenue This Year
- OPCH $10.80
- BPMC $44.85
- Revenue Next Year
- OPCH $8.63
- BPMC $32.06
- P/E Ratio
- OPCH $25.43
- BPMC N/A
- Revenue Growth
- OPCH 16.98
- BPMC 99.19
- 52 Week Low
- OPCH $21.39
- BPMC $73.04
- 52 Week High
- OPCH $35.53
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- OPCH 45.18
- BPMC 59.54
- Support Level
- OPCH $31.11
- BPMC $87.03
- Resistance Level
- OPCH $33.70
- BPMC $104.86
- Average True Range (ATR)
- OPCH 1.33
- BPMC 3.86
- MACD
- OPCH 0.03
- BPMC 1.24
- Stochastic Oscillator
- OPCH 53.04
- BPMC 64.38
About OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders among others.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.